Lv4
510 积分 2023-07-10 加入
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
9个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
9个月前
已完结
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations
9个月前
已完结
Overview and Current Status of Peptide Receptor Radionuclide Therapy
9个月前
已完结
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges
10个月前
已完结
Efficacy and Safety of 177Lu-DOTA-IBA in Tumor Bone Metastasis Treatment
10个月前
已完结
皖公网安备34019202002308
